Share on StockTwits

Dendreon (NASDAQ:DNDN) released its earnings data on Wednesday. The company reported ($0.18) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.18), American Banking and Market News reports.

A number of research firms have recently commented on DNDN. Analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note on Thursday, August 14th. They now have a $1.50 price target on the stock. On the ratings front, analysts at R. F. Lafferty downgraded shares of Dendreon from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Dendreon in a research note on Wednesday, August 13th. They now have a $1.50 price target on the stock, down previously from $2.50. Eight analysts have rated the stock with a sell rating and ten have given a hold rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $2.24.

Dendreon (NASDAQ:DNDN) opened at 1.35 on Wednesday. Dendreon has a 52-week low of $1.24 and a 52-week high of $3.52. The stock has a 50-day moving average of $2.02 and a 200-day moving average of $2.43. The company’s market cap is $209.8 million.

Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.